Sagimet Biosciences Inc.: Sagimet Biosciences Receives FDA "Study May Proceed" Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
Sagimet Biosciences (Nasdaq: SGMT) said the FDA cleared its IND and issued a “Study May Proceed” letter for denifanstat, a Phase 3 FASN inhibitor for moderate to severe acne. The trial is planned to start in 2H 2026, enrolling about 800 U.S. patients (450 adolescents). Dosing is 50 mg once daily vs placebo for 12 weeks, with a 40-week open-label extension.
How this was made
The 30-second read
Why it matters
The FDA’s “Study May Proceed” letter and IND clearance de-risk the start of the Phase 3 program and provide a dated initiation window (second half of 2026), which can shift probability-weighted development timelines.
Market read
Traders may re-rate SGMT on reduced regulatory friction and improved visibility into Phase 3 initiation, while still awaiting efficacy and safety outcomes.
What to watch
Trial execution risk (site readiness, enrollment pace for ~800 patients including adolescents) and endpoint performance against co-primary measures could dominate the next valuation step.
Background
Sagimet is a clinical-stage biopharma developing denifanstat, an oral once-daily FASN inhibitor, for moderate to severe acne; this release follows FDA review of its IND for Phase 3.
Ticker impact
FDA cleared Sagimet’s IND and issued a “Study May Proceed” letter for denifanstat Phase 3 acne trial, targeting initiation in 2H 2026.
Likely positive bias for SGMT as traders price reduced regulatory risk and a clearer path to Phase 3 dosing and future readouts.
The article reports a specific FDA action (IND clearance plus “Study May Proceed”) and provides concrete trial timing (initiate in 2H 2026) and scale (about 800 US patients).
Market effects
Supports sentiment for FASN-inhibitor and metabolic/fibrotic pathway acne programs by demonstrating regulatory progress into Phase 3.
Primarily US clinical-regulatory milestone; limited direct regional spillover beyond biotech development peers.
Denifanstat is developed by Ascletis in China and Sagimet elsewhere, so US Phase 3 progress can strengthen global development credibility.
Counterpoint
IND clearance does not guarantee Phase 3 success; efficacy and safety at week 12 and through the 40-week extension remain the main risk.
Key entities
- companySagimet Biosciences Inc.
Nasdaq-listed clinical-stage biopharmaceutical company receiving FDA IND clearance for denifanstat Phase 3 acne.
- drugdenifanstat
Oral once-daily FASN inhibitor in Phase 3 development for moderate to severe acne.
- regulatorU.S. Food and Drug Administration (FDA)
Cleared Sagimet’s IND and issued a “Study May Proceed” letter for the Phase 3 trial.
- partnerAscletis BioScience Co. Ltd.
License partner developing denifanstat as ASC40 in China.
